Home > Healthcare > Medical Devices > Medical Equipment > Intravenous (IV) Equipment Market

Intravenous (IV) Equipment Market Trends

Report ID: GMI4017
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Intravenous Equipment Market Trends

Chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions have become increasingly prevalent worldwide. For instance, according to the American Autoimmune Related Diseases Association (AARDA), there are over 100 identified autoimmune diseases, and they collectively affect more than 50 million people in the U.S. Furthermore, according to the International Agency for Research on Cancer (IARC) in December 2020, global estimates indicate that approximately 1 in 5 individuals will develop cancer at some point in their lifetime. IV equipment enables healthcare professionals to administer medications, fluids, and nutrients directly into the patient's veins, ensuring efficient and targeted delivery. The growing incidence of chronic diseases, coupled with the need for effective treatment.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Intravenous (IV) equipment market size was USD 14.4 billion in 2022 and is estimated to reach USD 27.2 billion by 2032 driven by rising usage in healthcare setting for enabling healthcare professionals to deliver essential treatments and therapies effectively

The hospitals and clinics segment recorded over 34% of the market share in 2022 owing to the presence of advanced healthcare infrastructure and higher focus on patient safety ?

Demand for intravenous equipment in the U.S. reached USD 5.4 billion in 2022 and is predicted to witness substantial market growth through 2032 due to the expanding geriatric population base and the rising incidence of cancer in the country

Some key intravenous equipment providers include B. Braun Melsungen AG, 3M, Terumo Corporation, Abbott, Teleflex Incorporated, BD, Henry Schein, Inc., Smiths Medical, Baxter, Ascor S.A., Moog Inc., AngioDynamics., ICU Medical, Inc., Fresenius SE & Co. KGaA, and Animas LLC